Key result
The Roche 3rd-generation cTnT assay showed excellent agreement with the 2nd-generation assay (r=0.99; 95% CI 0.99-1.0; p<=0.0001), with concordance up to 0.2 microg/l.
Why the study?
Does the recalibrated Roche 3rd-generation cTnT assay agree with the 2nd-generation assay in patients admitted to the coronary care unit?
Population
77 patients admitted to the coronary care unit, mean age 66 +/- 16 years
Comparison
Roche 3rd-generation cTnT assay vs Roche 2nd-generation cTnT assay
Design
Cross-sectional
Authors
Loading...
Supports consistent troponin thresholds with the recalibrated assay in CCU patients; leaves open prospective outcome validation in broader cohorts.
Observational (n=77)
Does the recalibrated Roche 3rd-generation cTnT assay agree with the 2nd-generation assay in patients admitted to the coronary care unit?
Effect estimate: r = 0.99 (95% CI 0.99-1.0)
p-value: p=<=0.0001
The recalibration of the Roche 3rd-generation cTnT assay does not affect clinical decision limits up to 0.2 microg/l, ensuring consistency with the 2nd-generation assay for detecting increased cardiac risk.
Gaze et al. (2005) conducted an observational in Admitted to the coronary care unit (n=77). Roche 3rd-generation cTnT assay vs. Roche 2nd-generation cTnT assay was evaluated on Agreement between 2nd- and 3rd-generation cTnT assays (r = 0.99, 95% CI 0.99-1.0, p=<=0.0001). The Roche 3rd-generation cTnT assay showed excellent agreement with the 2nd-generation assay (r=0.99; 95% CI 0.99-1.0; p<=0.0001), with concordance up to 0.2 microg/l.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: